Furthermore, the 5-year survival rates of low and highly EZH2 expressing endometrial cancers were 80% and 56% respectively, and were independent of other known prognostic factors such as histologic type, grade, vascular invasion, depth of myometrial infiltration, and clinical FIGO stage. The gene discussed is EZH2; the disease is endometrial cancer.